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Abstract 
(309 words) 
Background: Clinical prediction models combine several predictors (risk or prognostic factors) to 
estimate the risk whether a particular condition is present (diagnostic model) or whether a certain 
event will occur in the future (prognostic model). Large numbers of diagnostic and prognostic 
prediction model studies are published each year and a tool facilitating their quality assessment is 
needed, e.g. to support systematic reviews and evidence syntheses. 
Objective: To introduce and describe the development of PROBAST, a tool for assessing the risk of 
bias and applicability of prediction model studies. 
Methods: Web-based Delphi procedure (involving 40 experts in the field of prediction model 
research) and refinement of the tool through piloting. The scope of PROBAST was determined with 
consideration of existing risk of bias tools and reporting guidelines, such as CHARMS, QUADAS, 
QUIPS, and TRIPOD. 
Results: After seven Delphi rounds, a final tool was developed which utilises a domain-based 
structure supported by signalling questions. PROBAST assesses the risk of bias of prediction model 
studies and any concerns for their applicability. Studies that PROBAST can be used for include those 
developing, validating, and extending a prediction model. We define risk of bias to occur when 
shortcomings in the study design, conduct or analysis lead to systematically distorted estimates of 
model predictive performance or to an inadequate model to address the research question. The 
predictive performance is typically evaluated using calibration and discrimination, and 
sometimes (notably in diagnostic model studies) classification measures. Applicability refers to the 
extent to which the prediction model study matches the systematic review question in terms of the 
target population, predictors, or outcomes of interest. 
PROBAST comprises 20 signalling questions grouped into four domains: participant selection, 
predictors, outcome, and analysis. 
Conclusions: PROBAST can be used to assess the risk of bias and any concerns for applicability of 
studies developing, validating or extending (adjusting) prediction, both diagnostic and prognostic, 
models.  
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Introduction  
(415 words) 
Prediction relates to determining the probability of something currently unknown. In the context of 
medical research, prediction typically relates to either diagnosis (probability of a certain condition 
being present but not yet detected) or prognosis (probability of developing a future outcome).(1-3) 
Prognosis does not only pertain to sick individuals or with an established diagnosis, but also to, for 
example, prognosis of pregnant women at risk of developing diabetes(4) or of individuals in the 
general population at risk of developing osteoporotic fractures(5). 
Prediction research includes predictor finding studies, prediction model development, validation and 
adjusting or updating  studies, and prediction model impact studies.(1) Predictor finding studies (also 
known as risk factor or prognostic factor studies) aim to identify which predictors independently 
contribute to the prediction of a diagnostic or prognostic outcome.(1, 6) Prediction model studies 
typically aim to develop, validate or adjust (e.g. extend) a multivariable prediction model. In a 
prediction model, multiple predictors are used in combination for estimating individual probabilities 
to inform and often guide individual care.(2, 7, 8) These models can either predict an individual’s 
probability of currently having a particular outcome or disease (diagnostic prediction model) or 
experiencing a particular outcome in the future (prognostic prediction model). Well known examples 
are the Wells rule for diagnosing deep venous thrombosis,(9) the Ottawa ankle rules for detecting 
fractures,(10, 11) QRISK2 for predicting cardiovascular risk,(12) and the PCPT risk calculator for 
prostate biopsies.(13) 
Prediction models, both diagnostic and prognostic, are widely used for a variety of medical domains 
and settings,(14-16) evidenced by the large number of models developed, especially in cancer,(17, 
18) neurology,(19, 20) and cardiovascular disease domains.(21) Prediction models are sometimes 
described as risk prediction models, predictive models, prediction indices or rules, or risk scores.(2, 8) 
Prediction model impact studies evaluate the effect of using a model to guide patient care compared 
to not using such a model, and focus on the effect of its use on clinical decision making, patient 
outcomes, or costs of care, using a comparative design.(1) 
Systematic reviews have a key role in evidence based medicine and in the development of clinical 
guidelines.(22-24) They are considered to provide the most reliable form of evidence for the effects 
of an intervention or diagnostic test.(25, 26) Review and synthesis of prediction model studies is a 
relatively new and evolving area. Systematic reviews of prediction models are increasingly 
undertaken to appraise and summarise evidence on the performance of prediction models.(1, 7, 27) 
They typically aim to systematically identify, appraise and summarise primary studies reporting the 
development or validation of one or more prediction models.(27) 
Quality assessment of included studies is a crucial step in any systematic review.(25, 26) The QUIPS 
tool has been developed to assess the risk of bias in predictor finding (prognostic factor) studies.(28) 
The methodological quality of studies investigating the impact of a prediction model using a 
comparative randomised design can be assessed using the revised Cochrane risk of bias 
tool (ROB 2.0)(29) or ROBINS-I for non-randomised comparative designs.(30) With the increased 
numbers of systematic reviews for prediction model studies, a tool facilitating quality assessment for 
individual prognostic and diagnostic prediction model studies is urgently needed. 
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We present PROBAST (Prediction model Risk Of Bias ASsessment Tool), a tool to appraise the quality 
of prediction model studies. The tool allows the assessment of risk of bias and concerns for the 
applicability of diagnostic and prognostic prediction model studies. PROBAST can be used to assess 
both model development and model validation studies, including those adjusting (e.g. extending) a 
prediction model (Box 1). We explicitly refer to the accompanying Explanation and Elaboration (E&E) 
paper for detailed explanations on how to use the PROBAST tool and how to make risk of bias and 
applicability judgements.[REF E&E paper] To the best of our knowledge, PROBAST is the first tool 
which has been rigorously developed for this purpose.  
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Methods – Development of PROBAST 
(840 words) 
Development of PROBAST was based on a four-stage approach for developing health research 
reporting guidelines: define the scope, review the evidence base, web-based Delphi procedure, and 
refine the tool through piloting.(31) Guidelines explicitly aimed at the development of quality 
assessment tools were not available at the time.(32) 
Development stage 1: Define the scope 
A steering group of nine experts in the area of prediction model studies and quality assessment tool 
development was established. This group agreed on key features of the desired scope of PROBAST 
through regular teleconferences and face-to-face meetings. The scope was further refined during the 
web-based Delphi procedure with a panel of 40 experts. 
It was agreed that PROBAST should not cover all multivariable diagnostic or prognostic studies but 
only primary studies that developed, validated or adjusted (e.g. extended) one or more multivariable 
prediction models for diagnosis or prognosis. A multivariable prediction model is defined as any 
combination or equation of two or more predictors for estimating the probability or risk of a 
diagnostic or prognostic outcome for an individual.(7, 8, 33-35) Hence, a relevant primary prediction 
model study was one that included a model development, model validation or model adjustment  (or 
a combination of these) for the purpose of making individualised predictions of a diagnostic or 
prognostic outcome (Box 1). Diagnostic and prognostic model studies often use different terms for 
the predictors and outcomes (Box 2). Studies using multivariable modelling techniques to identify 
predictors (e.g. risk or prognostic factors) associated with an outcome but not attempting to develop, 
validate or adjust (e.g. extend) a model for making individualised predictions are not covered by 
PROBAST.(6) Hence PROBAST is not intended for predictor finding studies and prediction model 
impact studies.  
PROBAST was designed to assess primary studies included in a systematic review. The group agreed 
that PROBAST would assess both the risk of bias and concerns for applicability of a study that 
evaluates (develops, validates or extends) a multivariable diagnostic or prognostic prediction model 
to be used for individualised predictions. A domain-based structure was adopted similar to that used 
in other risk of bias tools such as the revised Cochrane Risk of Bias tool,(29) QUADAS-2,(36) ROBINS-
I(30) and ROBIS.(37)  
Development stage 2: Review the evidence 
Three different approaches were used to provide an evidence base to inform the development of 
PROBAST: (1) identification of relevant methodological reviews in the area of prediction model 
research, (2) asking members of the steering group to identify relevant methodological studies, and 
(3) use of the Delphi procedure to ask members of the wider group to identify additional evidence. 
Identified literature was used to guide the scope and produce an initial list of signalling questions for 
consideration for inclusion in PROBAST.(1, 2, 6-8, 34, 35, 38-44) Signalling questions were grouped 
into common themes in order to identify possible domains. 
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Development stage 3: Web-based Delphi procedure 
A modified Delphi process was used to gain feedback and agreement on the scope, structure and 
content of PROBAST. Web-based surveys were developed to gather structured feedback for each 
round. The Delphi group included 40 members comprising methodological experts in the areas of 
prediction model research and quality assessment tool development, experienced systematic 
reviewers, commissioners, and representatives of reimbursements agencies. Different potential 
stakeholders were included to ensure that the views of end-users, methodological experts and 
decision makers were represented. 
The Delphi process consisted of seven rounds. Round 1 asked about the scope of the tool and it was 
agreed to focus on prediction model studies only and to follow a domain-based structure. Round 2 
aimed at identifying and finding a consensus regarding the relevant domains to be included. The 
signalling questions for domains were refined in rounds 3 to 5. Respondents were asked to rate each 
proposed signalling question for inclusion using a 1 to 5 Likert scale. They were also given the 
opportunity to provide suggested rephrasing, provide any supporting evidence (e.g. references to 
relevant studies) and suggest any missing signalling questions. Round 6 refined the domains and 
introduced further optional guidance for the use of PROBAST. In the last round, participants were 
sent the agreed draft version of PROBAST and given the opportunity to provide any final feedback. 
Development stage 4: Piloting and refining of the tool 
Five workshops on PROBAST were held at consecutive annual Cochrane Colloquia (Quebec 2013, 
Hyderabad 2014, Vienna 2015, Seoul 2016, Cape Town 2017) and numerous consecutive workshops 
with MSc and PhD students (e.g. MSc Epidemiology program of Utrecht University, The Netherlands, 
and Evidence Based Health Care program of Oxford University, UK). In these, we piloted the then 
current version of the PROBAST tool to gather feedback on the practical issues associated with using 
the tool so we could further refine and subsequently validate the tool. Finally, over thirty review 
groups have already piloted PROBAST versions, included the final version, in their reviews. Topics 
included cancer, cardiology, endocrinology, pulmonology and orthopaedics. 
All feedback received from these initiatives was used to further inform the content and structure of 
the PROBAST tool, wording of the signalling questions, and content of the guidance documents.[REF 
E&E paper]  
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Results – The PROBAST tool 
(1,508 words) 
What does PROBAST assess? 
PROBAST assesses both the risk of bias and concerns for applicability of primary studies that 
developed or validated one or more multivariable prediction models for diagnosis or 
prognosis (Boxes 1 and 2). Development of a prediction model can also include adding new 
predictors to established predictors, i.e. the extension of an existing prediction model. Similarly, 
validation of an existing model can be accompanied by adjusting (updating) and also extending of the 
model, i.e. the development of a new model. PROBAST is also applicable to these two 
situations (Box 1). A multivariable prediction model is defined as any combination or equation of two 
or more predictors for estimating the probability or risk for an individual.(7, 8, 33-35) 
Target users 
PROBAST was developed with authors of systematic reviews in mind and is therefore written from 
that perspective. Other potential users of PROBAST include organisations supporting decision 
making (e.g. NICE, IQWiG), researchers and clinicians with an interest in evidence-based medicine or 
involved in guideline development, journal editors and manuscript reviewers. 
Definition of risk of bias and applicability 
Bias is usually defined as presence of systematic error within a study leading to distorted or flawed 
study results, hampering the internal validity of that study. In prediction model development and 
validation, there are known features which make a study at risk of bias, although there is limited 
empirical evidence to demonstrate the most important sources of bias. We define risk of bias to 
occur when shortcomings in the study design, conduct or analysis lead to systematically distorted 
estimates of model predictive performance or to an inadequate model to address the research 
question. Model predictive performance is typically evaluated using calibration and discrimination, 
and sometimes (notably in diagnostic model studies) classification measures.(8) To understand bias 
in study estimates of model predictive performance, it helps to think about how a hypothetical 
methodologically robust prediction model (development or validation) study would have been 
designed, conducted and analysed. Many sources of bias identified in other medical research areas 
are also relevant to prediction model studies, such as blinding of assessors of study outcomes to 
other features of the study, and the use of consistent definitions and measurements for predictors 
and outcomes within the study. 
Concerns for the applicability of primary studies to the review question can arise when the study 
population, predictors or outcomes of a primary study differ from those specified in the review 
question. Applicability concerns may arise when participants in the prediction model study are from 
a different medical setting than the population defined in the review question. For example, 
participants in a primary prediction model study may be enrolled from a hospital setting but the 
review question specifically relates to participants in primary care. The reported prediction model 
discrimination and calibration may not be applicable, as patients in hospital settings typically have 
more severe disease than patients in primary care.(9, 45) 
For systematic reviews where eligibility criteria, predictors and outcomes of the primary studies, 
directly match the review question, there will be no concerns for applicability of a primary study for 
the review. However, typically systematic reviews have inclusion criteria that are broader than the 
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focus of the review question. The broader inclusion criteria allow for variation in the searching of the 
primary studies and thus require careful assessment of applicability of each primary study to the 
actual review question.(8)[REF E&E paper] 
Types of prediction model study 
A primary study identified as relevant for the review may include the development, validation or 
update of one or more prediction models. For each study, a PROBAST assessment should be 
completed for each distinct model that is developed, validated, or adjusted (e.g. extended) for 
making individualised predictions, relevant to the systematic review question. 
PROBAST includes four steps. We stress the importance of the accompanying Explanation and 
Elaboration paper which provides detailed explanations and guidance carrying out each step.[REF 
E&E paper] 
Step Task When to complete 
1 Specify your systematic review 
question(s) 
Once per systematic review 
2 Classify the type of prediction model 
evaluation 
Once for each model of interest in each 
publication being assessed, for each relevant 
outcome 
3 Assess risk of bias and applicability 
(per domain) 
Once for each development and validation of 
each distinct prediction model in a publication 
4 Overall judgment of risk of bias and 
applicability 
Once for each development and validation of 
each distinct prediction model in a publication 
 
Step 1: Specify your systematic review question 
Assessors are first asked to report their systematic review question based on the guidance given in 
the CHARMS checklist.(41) 
Step 2: Classify the type of prediction model evaluation 
Different signalling questions apply for different types of prediction model evaluation. For each 
model assessment, reviewers classify a model as “development only”, “development and validation 
in the same publication” or “validation only”. When a publication focuses on adding one or more 
new predictors to established predictors, “development only” should be used. When a publication 
focuses on validation of an existing model in other data though followed by adjusting (updating) or 
extending of the model such that in fact a new model is being developed, then “development and 
validation in the same publication” should be used. Note again that sometimes a single publication 
may address more than one model of interest. 
Step 3: Assess risk of bias and applicability 
Step 3 aims to identify areas where bias may be introduced into the prediction model study or where 
there may be concerns for applicability. It involves the assessment of four domains to cover key 
aspects of prediction model studies: (1) participant selection, (2) predictors, (3) outcome, and 
(4) analysis. The risk of bias component of each domain comprises four sections: information used to 
support the judgment, 20 signalling questions (2 to 9 per domain), judgment of risk of bias, and 
rationale regarding the judgment (Table 1). 
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The support for judgement box provides space to record the information used to answer the 
signalling questions. Signalling questions are rated as yes (Y), probably yes (PY), probably no (PN), 
no (N) or no information (NI). Risk of bias is judged as “low”, “high”, or “unclear”.’ All signalling 
questions are phrased so that “yes” indicates absence of bias. Any signalling question rated as “no” 
or “probably no” flags the potential for bias; assessors will need to use their own judgment to 
determine whether the domain should be rated as “high”, “low” or “unclear” risk of bias. A “no” 
rating does not automatically result in a “high” risk of bias rating. The “no information” category 
should be used only when insufficient information is reported to permit a judgment. By recording the 
rationale for the risk of bias rating, the rating will be transparent and, where necessary, facilitate 
discussion among review authors completing assessments independently. 
The first three domains are also rated for concerns for applicability (low / high / unclear) to the 
review question defined above. Concerns for applicability are rated in a similar way to risk of bias but 
there are no signalling questions. 
All domains should be completed separately for each evaluation of a distinct model in each study. 
The team completing a PROBAST assessment is likely to need both subject content and 
methodological expertise to complete an assessment. For further details on how to score risk of bias 
and applicability concerns we refer to the E&E paper and www.probast.org.[REF E&E paper] 
 Domain 1 (Participant selection) covers potential sources of bias and applicability concerns 
related to how participants were selected for enrolment into the study and the data sources 
(e.g. study designs) used. Three signalling questions support the assessment of risk of bias. 
 Domain 2 (Predictors) covers potential sources of bias and applicability concerns related to 
the definition and measurement of the predictors evaluated for inclusion in the prediction 
model. Four signalling questions support the assessment of risk of bias. 
 Domain 3 (Outcome) covers potential sources of bias and applicability concerns related to 
the definition and measurement of the outcome that is predicted by the model. Seven 
signalling questions support the assessment of risk of bias. 
 Domain 4 (Analysis) covers potential sources of bias regarding the statistical analysis 
methods. It assesses aspects related to the choice of analysis method and whether key 
statistical considerations (e.g. in regards to missing data) were correctly addressed. Nine 
signalling questions support the assessment of risk of bias. 
Table 1 presents an overview of step 3. Detailed examples how to rate signalling questions and judge 
domains can be found in the E&E publication and on www.probast.org.[REF E&E paper] 
Step 4: Overall judgement 
Based on the risk of bias classifications for each domain in step 3, an overall judgement about risk of 
bias of the prediction model should be made. An overall rating of either low, high, or unclear risk of 
bias should be used. We recommend rating the prediction model to be of a low risk of bias if no 
relevant shortcomings were identified in the risk of bias assessment, i.e. all domains were rated as 
“low risk of bias”. If at least one domain was judged to be of high risk of bias, an overall judgement of 
high risk of bias should be used. Similarly, unclear risk of bias should be assigned once an unclear risk 
of bias was noted in at least one domain and it was low risk for all other domains. 
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However, if a prediction model was developed without any (external) validation and even all four 
domains were rated as low risk of bias, downgrading to high risk of bias should still be considered 
unless the model development was based on a very large data set and included some form of 
internal validation. For details we refer to the E&E paper.[REF E&E paper] 
Based on the applicability classifications for each domain in step 3, an overall judgement about the 
concerns for applicability of the prediction model is needed. A “low concern” decision should only be 
reached if all domains showed low concerns for applicability. Similarly, if one or more domains were 
judged to have high concerns for applicability, the overall judgement should be “high concern”. 
“Unclear concerns for applicability” should only be reached if one or more domains are judged as 
“unclear” for applicability and all other domains were rated to have “low concerns”.  
Detailed explanation and examples on how to judge the overall risk of bias and concerns for 
applicability can be found in the E&E publication and on www.probast.org.[REF E&E paper] Table 2 
suggests a way to present the results of the PROBAST assessments.  
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Discussion 
[245 words] 
Assessment of the quality of included studies is an essential component of all systematic reviews and 
evidence syntheses. Systematic reviews of prediction model studies are a rapidly evolving area.(27) 
PROBAST is the first rigorously developed tool designed specifically to assess the quality of prediction 
model studies for development, validation or updating models for both diagnostic and prognostic 
models. 
Explicit guidance and explanation about how to use PROBAST is provided in the E&E paper.[REF E&E 
paper] To understand and use the PROBAST tool, we stress that this E&E paper should be read in 
conjunction with the current paper. A multidisciplinary team, combining both subject content and 
methodological expertise, should ideally be used when assessing prediction model studies. 
Detailed examples and future revisions of the tool will be made available via the website; please 
check this website to ensure that you have the current version of the tool. We welcome feedback 
from users via www.probast.org. 
We adopted a domain based structure similar to that used in other recently developed tools such as 
the revised Cochrane risk of bias tool (ROB 2.0),(29) QUADAS-2 for diagnostic accuracy studies,(36) 
ROBINS-I for non-randomised studies,(30) and ROBIS for systematic reviews.(37) All stages of 
PROBAST development included a wide range of stakeholders with piloting starting with early 
versions of the tool allowing feedback from direct reviewer experience to be incorporated into the 
final tool. We feel that these two features have resulted in a tool that is both methodologically sound 
and user-friendly.  
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Table 1. Overview of step 3 (Assessment of risk of bias and concerns for applicability) 
 1. Participant selection 2. Predictors 3. Outcome 4. Analysis 
Si
gn
al
lin
g 
q
u
e
st
io
n
s 
1.1 Were appropriate data sources 
used, e.g. cohort, RCT or nested case-
control study data? 
2.1 Were predictors defined and 
assessed in a similar way for all 
participants? 
3.1 Was the outcome determined 
appropriately? 
4.1 Were there a reasonable number of participants 
with the outcome? 
1.2 Were all inclusions and exclusions of 
participants appropriate? 
2.2 Were predictor assessments made 
without knowledge of outcome data? 
3.2 Was a pre-specified or standard 
outcome definition used? 
4.2 Were continuous and categorical predictors 
handled appropriately? 
 
2.3 Are all predictors available at the 
time the model is intended to be used? 
3.3 Were predictors excluded from the 
outcome definition? 
4.3 Were all enrolled participants included in the 
analysis? 
–  
3.4 Was the outcome defined and 
determined in a similar way for all 
participants? 
4.4 Were participants with missing data handled 
appropriately? 
– – 
3.5 Was the outcome determined without 
knowledge of predictor information? 
4.5 Was selection of predictors based on univariable 
analysis avoided? [D] 
– – 
3.6 Was the time interval between 
predictor assessment and outcome 
determination appropriate? 
4.6 Were complexities in the data (e.g. censoring, 
competing risks, sampling of controls) accounted for 
appropriately? 
– –  
4.7 Were relevant model performance measures 
evaluated appropriately? 
– – – 
4.8 Was model overfitting, underfitting and optimism 
in model performance accounted for? [D] 
– – – 
4.9 Do predictors and their assigned weights in the final 
model correspond to the results from the reported 
multivariable analysis? [D] 
R
O
B
 
Selection of participants Predictors or their assessment Outcome or its determination Analysis 
A
p
p
lic
ab
ili
ty
 
Included participants and setting do not 
match the review question 
Definition, assessment or timing of 
predictors in the model do not match 
the review question 
Outcome, its definition, timing or 
determination do not match the review 
question 
– 
Signalling questions are rated as yes (Y), probably yes (PY), probably no (PN), no (N) or no information (NI). Risk of bias and concerns for applicability are rated as low, high, or unclear. 
D = Development studies only; ROB = Risk of bias; V = Validation studies only 
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Table 2. Suggested Tabular Presentation for PROBAST Results 
Study Risk of bias Applicability Overall 
Participant 
selection 
Predictors Outcome Analysis Participant 
selection 
Predictors Outcome Risk of 
bias 
Applicability 
Study 1 + - ? + + + + - + 
Study 2 + + + + + + + + + 
Study 3 + + + ? - + + ? - 
Study 4 - ? ? - + + - - - 
Study 5 + + + + + ? + + ? 
Study 6 + + + + ? + ? + ? 
Study 7 ? ? + ? + + + ? + 
Study 8 + + + + + + + + + 
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Boxes 
Box 1. Types of diagnostic and prognostic modelling studies or reports addressed by PROBAST 
(adopted from the TRIPOD and CHARMS guidance(8, 41)) 
Prediction model development without (external) validation 
These studies aim to develop one or more prognostic or diagnostic prediction models from a specific 
development data set. They aim to identify the important predictors of the outcome under study, assign 
weights (e.g. regression coefficients) to each predictor using some form of multivariable analysis, develop a 
prediction model to be used for individualised predictions, and quantify the predictive performance of that 
model in the development set. Sometimes, model development studies may also focus on adding one or more 
new predictors to established predictors. In any prediction model study, overfitting may occur, particularly in 
small data sets. Hence, development studies should ideally include some form of resampling or "internal 
validation” (internal because no data other than the development sample are used), such as bootstrapping or 
cross-validation. These methods quantify any optimism (bias) in the predictive performance of the developed 
model. 
 
Prediction model development with (external) validation 
Studies that have the same aim as the previous type, but the development of the model is followed by 
quantifying the model predictive performance in data external to the development sample. This may be data 
collected by the same investigators, commonly using the same predictor and outcome definitions and 
measurements, but sampled from a later time period (temporal validation); by other investigators in another 
hospital or country, sometimes using different definitions and measurements (geographic validation); in similar 
participants, but from an intentionally chosen different setting (e.g. model developed in secondary care and 
tested in similar participants from primary care); or even in other types of participants (e.g. model developed in 
adults and tested in children). Randomly splitting a single data set into a development and a validation data set 
is often erroneously referred to as a form of external validation, but actually is an inefficient form of "internal" 
validation, because the two so created data sets only differ by chance and sample size of model development is 
reduced. 
 
Prediction model (external) validation 
These studies aim to assess the predictive performance of one or more existing prediction models by using 
other participant data that were not used (i.e. external to) in the development of the model. When a model 
predicts poorly when validated in other data, a model validation can be followed by adjusting (or updating the 
existing model (e.g. by recalibration of the baseline risk or hazard or adjusting the weights of the predictors in 
the model) to the validation data set at hand, and even by extending the model by adding new predictors to 
the existing model. In both situations in fact a new model is being developed after the external validation of 
the existing model. 
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Box 2. Differences between diagnostic and prognostic prediction model studies 
Diagnostic prediction models aim to estimate the probability that a target condition measured using a 
reference standard (referred to as outcome in PROBAST) is currently present or absent within an individual. In 
diagnostic prediction model studies, the prediction is for an outcome already present so the preferred design is 
a cross-sectional study although sometimes follow-up is used as part of the reference test to determine the 
target condition presence at the moment of prediction.  
 
Prognostic prediction models estimate whether an individual will experience a specific event or outcome within 
a certain time period, ranging from minutes to hours, days, weeks, months or years: always a longitudinal 
relationship.  
 
Despite the different timing of the predicted outcome, there are many similarities between diagnostic and 
prognostic prediction models, including:  
 Type of outcome is often binary (target condition or disease presence (yes/no) or future occurrence of 
an outcome event (yes/no).  
 Key interest is to estimate the probability of an outcome being present or occurring in the future 
based on multiple predictors with the purpose of informing individuals and guiding decision-making. 
 Same challenges when developing or validating a multivariable prediction model. The same measures 
for assessing predictive performance of the model can be used although diagnostic models more 
commonly extend assessment of predictive performance to focus on thresholds of clinical relevance. 
 
There are also various differences in terminology between diagnostic and prognostic model studies:  
 
Diagnostic prediction model study Prognostic prediction model study 
Predictors 
Diagnostic tests or index tests Prognostic factors or prognostic indicators 
Outcome 
Reference standard used to assess or verify 
presence/absence of target condition 
Event (future occurrence yes or no) 
Event measurement 
Missing outcome assessment 
Partial verification, lost to follow-up Lost to follow-up and censoring 
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Appendix 
To ensure the use of the latest version download from the website www.probast.org. 
PROBAST 
(Prediction model study Risk Of Bias Assessment Tool) 
What does PROBAST assess? 
PROBAST assesses both the risk of bias and concerns for applicability of a study that evaluates (develops, 
validates or adjusts) a multivariable diagnostic or prognostic prediction model. It is designed to assess 
primary studies included in a systematic review. 
 
Bias occurs if systematic flaws or limitations in the design, conduct or analysis of a primary study distort the 
results. For the purpose of prediction modelling studies, we define risk of bias to occur when shortcomings 
in the study design, conduct or analysis lead to systematically distorted estimates of model predictive 
performance or to an inadequate model to address the research question. Model predictive performance is 
typically evaluated using calibration and discrimination, and sometimes (notably in diagnostic model 
studies) classification measures, and these are likely inaccurately estimated in studies with high risk of bias. 
Applicability refers to the extent to which the prediction model from the primary study matches your 
systematic review question, for example in terms of the participants, predictors or outcome of interest. 
 
A primary study may include the development, validation or adjustment of more than one prediction 
model. A PROBAST assessment should be completed for each distinct model that is developed, validated or 
adjusted in a study, so there may be more than one PROBAST assessment for a primary study. Assessors are 
advised to focus only on the prediction models included in a study that are of interest for the systematic 
review question. Where a publication assesses multiple prediction models, only complete a PROBAST 
assessment for those models that meet the inclusion criteria for your systematic review. Please note that 
subsequent use of the term “model” includes derivatives of models, such as simplified risk scores, 
nomograms, or recalibrations of models. 
 
PROBAST can be used to assess any type of diagnostic or prognostic prediction model examining 
individualised predictions, regardless of the predictors used, outcomes being predicted, or method to 
develop, validate or adjust the model. 
 
PROBAST includes four steps. 
Step Task When to complete 
1 Specify your systematic review 
question(s) 
Once per systematic review 
2 Classify the type of prediction model 
evaluation 
Once for each model of interest in each publication 
being assessed, for each relevant outcome 
3 Assess risk of bias and applicability (per 
domain) 
Once for each development and validation of each 
distinct prediction model in a publication 
4 Overall judgment of risk of bias and 
applicability 
Once for each development and validation of each 
distinct prediction model in a publication 
 
If this is your first time using PROBAST, we strongly recommend reading the detailed explanation and 
elaboration (E&E) paper and to check the examples on www.probast.org. 
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Step 1: Specify your systematic review question 
State your systematic review question to facilitate the assessment of the applicability of the evaluated models 
to your question. The following table should be completed once per systematic review. 
 
Criteria Specify your systematic review question 
Intended use of model:   
Participants including 
selection criteria and 
setting: 
 
Predictors (used in 
modelling) including (1) 
types of predictors (e.g. 
history, clinical 
examination, biochemical 
markers, imaging tests), 
(2) time of measurement, 
(3) specific measurement 
issues (e.g. any 
requirements/ prohibitions 
for specialised equipment): 
 
Outcome to be predicted:   
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Step 2: Classify the type of prediction model evaluation 
Use the following table to classify the evaluation as model development, model validation, or combination. 
Different signalling questions apply for different types of prediction model evaluation.  
When a publication focuses on adding one or more new predictors to established predictors then use 
“development only”. When a publication focuses on validation of an existing model in other data though 
followed by adjusting (updating) or extending of the model such that in fact a new model is being developed, 
then use “development and validation in the same publication”. 
If the evaluation does not fit one of these classifications then PROBAST should not be used. 
 
Classify the evaluation based on its aim  
Type of model evaluation Tick as 
appropriate 
PROBAST 
classification 
Prediction model development without testing its predictive 
performance in other individuals, i.e. no external validation. Model 
development should ideally include internal validation, such as 
bootstrapping or cross-validation. 
 Development (Dev) 
only 
Prediction model development as well as testing of predictive 
performance in other individuals (external validation), both in the 
same publication. 
 Development (Dev) 
and external validation 
(Val) 
Evaluating the predictive performance of a previously developed 
prediction model in other individuals (external validation). 
 External validation 
(Val) only 
 
This table should be completed once for each publication being assessed and for each relevant outcome in 
your review. 
Publication reference  
Models of interest  
Outcome of interest  
 
 
Step 3: Assess risk of bias and applicability 
PROBAST is structured as four key domains. Each domain is judged for risk of bias (low, high or unclear) and 
includes signalling questions to help make judgements. Signalling questions are rated as yes (Y), probably yes 
(PY), probably no (PN), no (N) or no information (NI). All signalling questions are phrased so that “yes” 
indicates absence of bias. Any signalling question rated as “no” or “probably no” flags the potential for bias; 
you will need to use your judgement to determine whether the domain should be rated as “high”, “low” or 
“unclear” risk of bias. The guidance document contains further instructions and examples on rating signalling 
questions and risk of bias for each domain. 
The first three domains are also rated for concerns for applicability (low/ high/ unclear) to your review 
question defined above.  
Complete all domains separately for each evaluation of a distinct model. Shaded boxes indicate where 
signalling questions do not apply and should not be answered. 
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DOMAIN 1: Participant selection   
A. Risk of Bias 
Describe the sources of data and criteria for participant selection: 
 
 
 Dev Val 
1.1 Were appropriate data sources used, e.g. cohort, RCT or nested case-control 
study data? 
  
1.2 Were all inclusions and exclusions of participants appropriate?   
Risk of bias introduced by selection of participants  
 
RISK: 
(low/ high/ unclear) 
  
Rationale of bias rating: 
 
 
B. Applicability 
Describe included participants, setting and dates:  
 
 
 
Concern that the included participants and setting do not 
match the review question   
CONCERN: 
(low/ high/ unclear) 
  
Rationale of applicability rating: 
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DOMAIN 2: Predictors   
A. Risk of Bias 
List and describe predictors included in the final model, e.g. definition and timing of assessment: 
 
 
 
 Dev Val 
2.1 Were predictors defined and assessed in a similar way for all participants?   
2.2 Were predictor assessments made without knowledge of outcome data?    
2.3 Are all predictors available at the time the model is intended to be used?   
Risk of bias introduced by predictors or their assessment RISK: 
(low/ high/ unclear) 
  
Rationale of bias rating: 
 
 
B. Applicability 
Concern that the definition, assessment or timing of 
predictors in the model do not match the review question  
CONCERN: 
(low/ high/ unclear) 
  
Rationale of applicability rating: 
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DOMAIN 3: Outcome 
A. Risk of Bias 
Describe the outcome, how it was defined and determined, and the time interval between predictor 
assessment and outcome determination: 
 
 
 
 
 Dev Val 
3.1 Was the outcome determined appropriately?   
3.2 Was a pre-specified or standard outcome definition used?   
3.3 Were predictors excluded from the outcome definition?   
3.4 Was the outcome defined and determined in a similar way for all participants?   
3.5 Was the outcome determined without knowledge of predictor information?   
3.6 Was the time interval between predictor assessment and outcome 
determination appropriate? 
  
Risk of bias introduced by the outcome or its 
determination   
RISK: 
(low/ high/ unclear) 
  
Rationale of bias rating: 
 
 
B. Applicability 
At what time point was the outcome determined: 
 
 
If a composite outcome was used, describe the relative frequency/distribution of each contributing 
outcome: 
 
 
Concern that the outcome, its definition, timing or 
determination do not match the review question 
CONCERN: 
(low/ high/ unclear) 
  
Rationale of applicability rating: 
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DOMAIN 4: Analysis 
Risk of Bias 
Describe numbers of participants, number of candidate predictors (for DEV only), outcome events 
and events per candidate predictor (for DEV only): 
 
 
Describe how the model was developed (predictor selection, optimism, risk groups, model performance): 
 
 
Describe whether and how the model was validated, either internally (e.g. bootstrapping, cross 
validation, random split sample) or externally (e.g. temporal validation, geographical validation, 
different setting, different type of participants): 
 
 
Describe the performance measures of the model, e.g. (re)calibration, discrimination, (re)classification, net 
benefit: 
 
 
Describe any participants who were excluded from the analysis: 
 
 
Describe missing data on predictors and outcomes as well as methods used for missing data: 
 
 
 Dev Val 
4.1 Were there a reasonable number of participants with the outcome?   
4.2 Were continuous and categorical predictors handled appropriately?   
4.3 Were all enrolled participants included in the analysis?   
4.4 Were participants with missing data handled appropriately?   
4.5 Was selection of predictors based on univariable analysis avoided?    
4.6 Were complexities in the data (e.g. censoring, competing risks, sampling of 
controls) accounted for appropriately? 
  
4.7 Were relevant model performance measures evaluated appropriately?   
4.8 Was model overfitting and optimism in model performance accounted for?   
4.9 Do predictors and their assigned weights in the final model correspond to the 
results from the reported multivariable analysis?  
  
Risk of bias introduced by the analysis  RISK: 
(low/ high/ unclear) 
  
Rationale of bias rating: 
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Step 4: Overall assessment 
Use the following tables to reach overall judgements about risk of bias and concerns for applicability of the 
prediction model evaluation (development and/or validation) across all assessed domains. 
Complete for each evaluation of a distinct model. 
 
Reaching an overall judgement about risk of bias of the prediction model evaluation 
Low risk of bias  If all domains were rated low risk of bias. 
If a prediction model was developed without any external validation, and it was rated 
as low risk of bias for all domains, consider downgrading to high risk of bias. Such a 
model can only be considered as low risk of bias, if the development was based on a 
very large data set and included some form of internal validation. 
High risk of bias  If at least one domain is judged to be at high risk of bias.  
Unclear risk of 
bias 
If an unclear risk of bias was noted in at least one domain and it was low risk for all 
other domains.  
 
Reaching an overall judgement about applicability of the prediction model evaluation 
Low concerns for 
applicability  
If low concerns for applicability for all domains, the prediction model 
evaluation is judged to have low concerns for applicability. 
High concerns for 
applicability  
If high concerns for applicability for at least one domain, the prediction model 
evaluation is judged to have high concerns for applicability. 
Unclear concerns for 
applicability  
If unclear concerns (but no “high concern”) for applicability for at least one 
domain, the prediction model evaluation is judged to have unclear concerns 
for applicability overall. 
 
 
Overall judgement about risk of bias and applicability of the prediction model evaluation 
Overall judgement of risk of bias RISK: 
(low/ high/ unclear) 
 
Summary of sources of potential bias: 
 
 
Overall judgement of applicability CONCERN: 
(low/ high/ unclear) 
 
Summary of applicability concerns: 
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